Bulk Manufacturer of Controlled Substances Application: Alltech Associates, Inc., 50041-50042 [2015-20283]
Download as PDF
<![CDATA[
50041
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
respondent in a particular case and the
community of registrants. See Gaudio,
74 FR at 10095 (quoting Southwood, 71
FR at 36503). Cf. McCarthy v. SEC, 406
F.3d 179, 188–89 (2d Cir. 2005)
(upholding SEC’s express adoption of
‘‘deterrence, both specific and general,
as a component in analyzing the
remedial efficacy of sanctions’’).
Having reviewed Respondent’s
Statement of Position, I conclude that he
has failed to produce sufficient evidence
to show why he should be entrusted
with a new registration. His acceptance
of responsibility is equivocal at best, as
while he appears to acknowledge his
wrongdoing with respect to his having
provided the Schedule II order forms to
Mr. Whitney, his explanation for why
he materially falsified his DEA
application is clearly disingenuous. So
too, is his assertion that he ‘‘did not
knowingly tell lies, nor . . .
intentionally try to deceive anyone.’’
Because Respondent committed
intentional misconduct when he
materially falsified his application, I
find his misconduct to be egregious.14
Accordingly, his failure to accept
responsibility for this misconduct is
reason alone to conclude that he cannot
be entrusted with a new registration.15
Moreover, the Agency has a manifest
interest in deterring misconduct on the
part of others who may contemplate
materially falsifying their applications
for registration. Accordingly, I conclude
that denial of his application is
necessary to protect the public interest.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f), as well as 28 CFR
0.100(b), I order that the application of
Arthur H. Bell, D.O., for a DEA
Certificate of Registration as a
practitioner be, and it hereby is, denied.
This Order is effective immediately.
Dated: August 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–20353 Filed 8–17–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Alltech
Associates, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before October 19, 2015.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on April
24, 2015, Alltech Associates, Inc., 2051
Waukegan Road, Deerfield, Illinois
60015 applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
ADDRESSES:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Controlled substance
Schedule
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ..............................................................................................................................................................
4-Methylaminorex (cis isomer) (1590) .........................................................................................................................................................
Gamma Hydroxybutyric Acid (2010) ...........................................................................................................................................................
Alpha-ethyltryptamine (7249) ......................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) (7348) ...............................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) .........................................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ..............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ..........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ..............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ..................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine (7431) .................................................................................................................................................
Alpha-methyltryptamine (7432) ...................................................................................................................................................................
Bufotenine (7433) ........................................................................................................................................................................................
Diethyltryptamine (7434) .............................................................................................................................................................................
Dimethyltryptamine (7435) ..........................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
14 Having found that Respondent’s material
falsification of his application is egregious and that
he has not accepted responsibility for the violation,
I need not decide whether the other proven
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
violations are sufficiently egregious to support the
denial of the application.
15 As to the violation in authorizing Whitney to
order schedule II drugs, Respondent stated that this
´
was the result of ‘‘pure naivete and ignorance of the
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
law on my part.’’ However, Respondent has offered
no evidence of remedial actions he has taken to
demonstrate that he is now familiar with the laws
and regulations applicable to the lawful dispensing
of controlled substances.
E:\FR\FM\18AUN1.SGM
18AUN1
50042
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
Controlled substance
Schedule
Psilocyn (7438) ............................................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine (7439) ..............................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine (7455) ....................................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine (7458) ....................................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ...............................................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C–E) (7509) .....................................................................................................................
2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) (7517) .................................................................................................................................
2-(4-lodo-2,5-dimethoxyphenyl) ethanamine (2C–I) (7518) ........................................................................................................................
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C–T–4) (7532) ....................................................................................................
Dihydromorphine (9145) ..............................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
1-Phenylcyclohexylamine (7460) .................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Ecgonine (9180) ..........................................................................................................................................................................................
Meperidine intermediate-B (9233) ...............................................................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories
and for distribution to its customers.
Dated: August 10, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–20283 Filed 8–17–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[Docket No. 13–29]
Drug Enforcement Administration
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Matthew Valentine/Liar Catchers;
Order
On April 5, 2013, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Matthew Valentine
(hereinafter, Applicant), of Lexington,
Kentucky. The Show Cause Order
proposed the denial of Applicant’s
pending application for a DEA
Certificate of Registration as a
Researcher, which would authorize
Applicant to possess and use controlled
substances as a canine handler, on the
ground that his registration would be
inconsistent with the public interest. GX
1, at 1 (citing 21 U.S.C. 823(f)).
On April 29, 2013, Applicant, acting
pro se, filed a request for a hearing with
the DEA Office of Administrative Law
Judges. GX 2. After the matter was
assigned to an Administrative Law
Judge (ALJ), Applicant submitted a
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
letter in which he requested to
withdraw his application. GX 3.
Therein, Applicant stated that he was
‘‘not in a position to fight this legal
battle at this time.’’ Id. A few weeks
later, Applicant requested a stay until
May 31, 2013, see GX 4, which was
granted by the ALJ. See GX 5.
Upon presentation of Applicant’s
withdrawal request to the Office of
Diversion Control (OD), the latter
advised Government Counsel that it
would accept the request only if
Applicant agreed not to reapply for
three years. Request for Final Agency
Action, at 3. Applicant rejected OD’s
offer. Id. Thereafter, OD made a
subsequent offer that would have
allowed Applicant to withdraw if he
agreed not to reapply for two years. Id.
Applicant also rejected this offer. Id.
According to Government Counsel, on
May 22, 2012, OD, ‘‘without providing
a basis for its decision,’’ notified the
former that it had rejected Applicant’s
withdrawal request and ‘‘instructed
Chief Counsel to take the matter to
hearing.’’ Id. The next day, Government
Counsel notified the ALJ of OD’s
decision. The ALJ then vacated the stay
and set the matter for hearing. GX 7, at
1–2.
On May 29, 2013, Applicant
submitted a request to waive his right to
a hearing and submitted various
documents in support of his
application. GX 8. The ALJ then ordered
that the proceeding be terminated. GX 9.
Thereafter, on October 29, 2013, the
Government submitted a Request for
Final Agency Action. Req. for Final
Agency Action, at 15. Therein, the
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
Government sought the denial of
Applicant’s application. Id. at 1.
Upon review, the then-Administrator
denied the Government’s request. Order
of the Administrator, at 3 (May 2, 2015)
(hereinafter, Order). The thenAdministrator specifically explained
that under a DEA regulation, ‘‘‘[a]n
application may be amended or
withdrawn with permission of the
Administrator at any time where good
cause is shown by the applicant or
where the amendment or withdrawal is
in the public interest.’’’ Id. at 2 (quoting
21 CFR 1301.16(a)). The thenAdministrator also relied on section
555(e) of the Administrative Procedure
Act, which provides that:
Prompt notice shall be given of the denial
in whole or in part of a written application,
petition, or other request of an interested
person made in connection with any agency
proceedings. Except in affirming a prior
denial or when the denial is self-explanatory,
the notice shall be accompanied by a brief
statement of the grounds for denial.
5 U.S.C. 555(e) (quoted in Order, at 2).
Based on the plain language of section
555(e), the then-Administrator held that
Applicant’s withdrawal request clearly
was a ‘‘request of an interested person
made in connection with [an] agency
proceeding.’’ Order, at 2. She further
noted that the grounds for denying
Applicant’s withdrawal request were
not ‘‘self-explanatory,’’ and were, in
fact, ‘‘totally unknown.’’ Id.
Accordingly, the then-Administrator
held that the Office of Diversion Control
was required to provide Applicant with
a ‘‘ ‘notice,’ ’’ which was ‘‘ ‘accompanied
by a brief statement of the grounds for
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 80, Number 159 (Tuesday, August 18, 2015)]
[Notices]
[Pages 50041-50042]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-20283]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Alltech
Associates, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before October 19, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODXL,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on April
24, 2015, Alltech Associates, Inc., 2051 Waukegan Road, Deerfield,
Illinois 60015 applied to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Methcathinone (1237)........................ I
N-Ethylamphetamine (1475)................... I
N,N-Dimethylamphetamine (1480).............. I
4-Methylaminorex (cis isomer) (1590)........ I
Gamma Hydroxybutyric Acid (2010)............ I
Alpha-ethyltryptamine (7249)................ I
Lysergic acid diethylamide (7315)........... I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine I
(2C-T-7) (7348).
Tetrahydrocannabinols (7370)................ I
Mescaline (7381)............................ I
4-Bromo-2,5-dimethoxyamphetamine (7391)..... I
4-Bromo-2,5-dimethoxyphenethylamine (7392).. I
4-Methyl-2,5-dimethoxyamphetamine (7395).... I
2,5-Dimethoxyamphetamine (7396)............. I
2,5-Dimethoxy-4-ethylamphetamine (7399)..... I
3,4-Methylenedioxyamphetamine (7400)........ I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine (7404) I
3,4-Methylenedioxymethamphetamine (7405).... I
4-Methoxyamphetamine (7411)................. I
5-Methoxy-N-N-dimethyltryptamine (7431)..... I
Alpha-methyltryptamine (7432)............... I
Bufotenine (7433)........................... I
Diethyltryptamine (7434).................... I
Dimethyltryptamine (7435)................... I
Psilocybin (7437)........................... I
[[Page 50042]]
Psilocyn (7438)............................. I
5-Methoxy-N,N-diisopropyltryptamine (7439).. I
N-Ethyl-1-phenylcyclohexylamine (7455)...... I
1-(1-Phenylcyclohexyl)pyrrolidine (7458).... I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) I
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine I
(2C-E) (7509).
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H) I
(7517).
2-(4-lodo-2,5-dimethoxyphenyl) ethanamine I
(2C-I) (7518).
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) I
ethanamine (2C-T-4) (7532).
Dihydromorphine (9145)...................... I
Heroin (9200)............................... I
Normorphine (9313).......................... I
Methamphetamine (1105)...................... II
1-Phenylcyclohexylamine (7460).............. II
Phencyclidine (7471)........................ II
Phenylacetone (8501)........................ II
1-Piperidinocyclohexanecarbonitrile (8603).. II
Cocaine (9041).............................. II
Codeine (9050).............................. II
Dihydrocodeine (9120)....................... II
Ecgonine (9180)............................. II
Meperidine intermediate-B (9233)............ II
Morphine (9300)............................. II
Noroxymorphone (9668)....................... II
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical applications only in clinical, toxicological, and
forensic laboratories and for distribution to its customers.
Dated: August 10, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-20283 Filed 8-17-15; 8:45 am]
BILLING CODE 4410-09-P
